First Trimester Exposure to Anxiolytic and Hypnotic Drugs and the Risks of Major Congenital Anomalies: A United Kingdom Population-Based Cohort Study

Background Despite their widespread use the effects of taking benzodiazepines and non-benzodiazepine hypnotics during pregnancy on the risk of major congenital anomaly (MCA) are uncertain. The objectives were to estimate absolute and relative risks of MCAs in children exposed to specific anxiolytic and hypnotic drugs taken in the first trimester of pregnancy, compared with children of mothers with depression and/or anxiety but not treated with medication and children of mothers without diagnosed mental illness during pregnancy. Methods We identified singleton children born to women aged 15–45 years between 1990 and 2010 from a large United Kingdom primary care database. We calculated absolute risks of MCAs for children with first trimester exposures of different anxiolytic and hypnotic drugs and used logistic regression with a generalised estimating equation to compare risks adjusted for year of childbirth, maternal age, smoking, body mass index, and socioeconomic status. Results Overall MCA prevalence was 2.7% in 1,159 children of mothers prescribed diazepam, 2.9% in 379 children with temazepam, 2.5% in 406 children with zopiclone, and 2.7% in 19,193 children whose mothers had diagnosed depression and/or anxiety but no first trimester drug exposures. When compared with 2.7% in 351,785 children with no diagnosed depression/anxiety nor medication use, the adjusted odds ratios were 1.02 (99% confidence interval 0.63–1.64) for diazepam, 1.07 (0.49–2.37) for temazepam, 0.96 (0.42–2.20) for zopiclone and 1.27 (0.43–3.75) for other anxiolytic/hypnotic drugs and 1.01 (0.90–1.14) for un-medicated depression/anxiety. Risks of system-specific MCAs were generally similar in children exposed and not exposed to such medications. Conclusions We found no evidence for an increase in MCAs in children exposed to benzodiazepines and non-benzodiazepine hypnotics in the first trimester of pregnancy. These findings suggest that prescription of these drugs during early pregnancy may be safe in terms of MCA risk, but findings from other studies are required before safety can be confirmed.

[1]  A. Coomarasamy,et al.  Antenatal and postnatal mental health , 2016 .

[2]  S. Pilling,et al.  Antenatal and postnatal mental health: summary of updated NICE guidance , 2014, BMJ : British Medical Journal.

[3]  T. Coleman,et al.  Completeness of Maternal Smoking Status Recording during Pregnancy in United Kingdom Primary Care Data , 2013, PloS one.

[4]  L. Tata,et al.  Potential of general practice data for congenital anomaly research: Comparison with registry data in the United Kingdom. , 2013, Birth defects research. Part A, Clinical and molecular teratology.

[5]  Ronan A Lyons,et al.  UK health performance: findings of the Global Burden of Disease Study 2010 , 2013, BDJ.

[6]  C. Bellantuono,et al.  Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. , 2013, General hospital psychiatry.

[7]  L. Brandt,et al.  Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study , 2012, BMJ : British Medical Journal.

[8]  L. Tata,et al.  Impact of socioeconomic deprivation on maternal perinatal mental illnesses presenting to UK general practice. , 2012, The British journal of general practice : the journal of the Royal College of General Practitioners.

[9]  J. West,et al.  Live and Non-Live Pregnancy Outcomes among Women with Depression and Anxiety: A Population-Based Study , 2012, PloS one.

[10]  F. Oyebode,et al.  Psychotropics in pregnancy: safety and other considerations. , 2012, Pharmacology & therapeutics.

[11]  L. Brandt,et al.  Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. , 2012, Archives of general psychiatry.

[12]  N. Gilhus,et al.  Pregnancy complications in patients with epilepsy , 2012, Current opinion in obstetrics & gynecology.

[13]  C. Parker,et al.  Causes of death among stillbirths. , 2011, JAMA.

[14]  B. Källén,et al.  Are Hypnotic Benzodiazepine Receptor Agonists Teratogenic in Humans? , 2011, Journal of clinical psychopharmacology.

[15]  Lisa Szatkowski,et al.  Can data from primary care medical records be used to monitor national smoking prevalence? , 2011, Journal of Epidemiology & Community Health.

[16]  R. Charlton,et al.  Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as Tools for Postmarketing Teratogen Surveillance , 2011, Drug safety.

[17]  G. Koren,et al.  The fetal safety of benzodiazepines: an updated meta-analysis. , 2011, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[18]  M. Cunnington,et al.  Identifying Major Congenital Malformations in the UK General Practice Research Database (GPRD) , 2010, Drug safety.

[19]  Richard A. Armstrong,et al.  Sample size estimation and statistical power analyses , 2010 .

[20]  I. Mylonas,et al.  Managing hyperemesis gravidarum: a multimodal challenge , 2010, BMC medicine.

[21]  A. Olshan,et al.  Validation of neural tube defects in the full featured—general practice research database , 2008, Pharmacoepidemiology and drug safety.

[22]  C. Hertzman,et al.  Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. , 2008, Birth defects research. Part B, Developmental and reproductive toxicology.

[23]  R. Charlton,et al.  Data Resources for Investigating Drug Exposure during Pregnancy and Associated Outcomes , 2008, Drug safety.

[24]  B. Källén,et al.  Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations , 2007, Pharmacoepidemiology and drug safety.

[25]  H A Guess,et al.  The utility of the general practice research database to examine selected congenital heart defects: a validation study , 2007, Pharmacoepidemiology and drug safety.

[26]  W. Bilker,et al.  Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research , 2007, Pharmacoepidemiology and drug safety.

[27]  H. Guess,et al.  Evaluation of the General Practice Research Database congenital heart defects prevalence: comparison to United Kingdom national systems. , 2007, Birth defects research. Part A, Clinical and molecular teratology.

[28]  E. Horváth-Puhó,et al.  Use of phenytoin, phenobarbital, or diazepam during pregnancy and risk of congenital abnormalities: a case‐time‐control study , 2007, Pharmacoepidemiology and drug safety.

[29]  Allan Donner,et al.  The prevalence of stillbirths: a systematic review , 2006, Reproductive health.

[30]  James W. Hardin,et al.  Generalized Estimating Equations (GEE) , 2005 .

[31]  H. Dolk EUROCAT: 25 years of European surveillance of congenital anomalies , 2005, Archives of Disease in Childhood - Fetal and Neonatal Edition.

[32]  D. Mehta British National Formulary (BNF) 51 , 2005 .

[33]  Cemach Confidential Enquiry into Maternal and Child Health , 2005 .

[34]  J. Olsen,et al.  A population-based case-control study of oral chlordiazepoxide use during pregnancy and risk of congenital abnormalities. , 2004, Neurotoxicology and teratology.

[35]  M. Bonati,et al.  Use of psychotropic drugs during pregnancy , 1993, European Journal of Clinical Pharmacology.

[36]  H. Sørensen,et al.  Short-Term Oral Diazepam Treatment during Pregnancy , 2003, Clinical drug investigation.

[37]  J. Astbury,et al.  Gender disparities in mental health , 2001 .

[38]  U. Bergman,et al.  Benzodiazepine use in pregnancy and major malformations or oral clefts , 1999, BMJ.

[39]  C. Cates Benzodiazepine use in pregnancy and major malformations or oral clefts. Pooled results are sensitive to zero transformation used. , 1999, British medical journal.

[40]  J. Boughman,et al.  Ebstein's malformation of the tricuspid valve: genetic and environmental factors. The Baltimore-Washington Infant Study Group. , 1994, Teratology.

[41]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[42]  O. Heinonen,et al.  Congenital heart disease in the offspring and maternal habits and home exposures during pregnancy. , 1992, Teratology.

[43]  D. Black HEALTH AND DEPRIVATION: Inequality and the north , 1988 .

[44]  A. Czeizel Lack of evidence of teratogenicity of benzodiazepine drugs in Hungary. , 1987, Reproductive toxicology.

[45]  S. Shapiro,et al.  Lack of relation of oral clefts to diazepam use during pregnancy. , 1983, The New England journal of medicine.

[46]  G. Oakley,et al.  ASSOCIATION BETWEEN CLEFT LIP WITH OR WITHOUT CLEFT PALATE AND PRENATAL EXPOSURE TO DIAZEPAM , 1975, The Lancet.

[47]  I. Saxén Associations between oral clefts and drugs taken during pregnancy. , 1975, International journal of epidemiology.

[48]  A. Blalock Surgical treatment of pulmonary stenosis. , 1947, Lancet.